Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Ziegelbauer
Copanlisib in Combination With Anti-Pd-1 Induces Regression in Animal Tumor Models Insensitive or Resistant to the Monotherapies of Pi3k and Checkpoint Inhibitors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
Frontiers in Oncology
Cancer Research
Oncology
P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Combination Therapy With Copanlisib and ABL Tyrosine Kinase Inhibitors Against Philadelphia Chromosome-Positive Resistant Cells
Oncotarget
Oncology
PD-L1 Checkpoint Blockade Delivered by Retroviral Replicating Vector Confers Anti-Tumor Efficacy in Murine Tumor Models
Oncotarget
Oncology
Infectious Complications Associated With the Use of Immune Checkpoint Inhibitors in Oncology: Reactivation of Tuberculosis After Anti PD-1 Treatment
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model
International Journal of Endocrinology
Endocrine
Endocrinology
Metabolism
Autonomic Systems
Diabetes
Combination of Chemotherapy and PD-1 Blockade Induces T Cell Responses to Tumor Non-Mutated Neoantigens
Communications Biology
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis
BMC Cancer
Cancer Research
Oncology
Genetics
Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine
Medicine
